US 9,199,912 · Application 14/259,964 · Granted Dec 1, 2015
US 9,199,912
Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same
Estimated expiration
September 28, 2031
4y 340d remaining
- Could not fetch continuity data for application PCTCN2011001637: Resource not found (404)
Earliest effective filing
Sep 28, 2011
+ 20 years
Sep 28, 2031
PTA +0d
Sep 28, 2031
No TD
—
Final
Sep 28, 2031
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- April 23, 2014
- Earliest effective filing
- September 28, 2011
- Issue date
- December 1, 2015
- PTA
- 0 days
- Base expiry (before PTA)
- September 28, 2031
September 28, 2011 + 20 years = September 28, 2031
- Continuation of application 13/846,773, filed Mar 18, 2013, issued as US 8,741,952
- Continuation-in-part of application PCTCN2011001637, filed Sep 28, 2011
- Continuation-in-part of application PCTCN2011001637, filed Sep 28, 2011
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 14/259,964 · US 9,199,912
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 9,199,912: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US9199912Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.